| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Restricted cash | NaN | NaN | 840 | 748 |
| Cash and cash equivalents | 1,491 | 578 | NaN | 0 |
| Restricted cash and cash equivalents | 888 | NaN | NaN | NaN |
| Trade accounts receivable, net | 560 | 12,480 | 4,435 | 4,934 |
| Inventories | 1,890 | 1,129 | 1,684 | 1,906 |
| Prepaid and other current assets | 1,227 | 1,097 | 959 | 1,382 |
| Total current assets | 6,056 | 15,284 | 7,918 | 8,970 |
| Property and equipment, gross | 535 | 534 | 532 | NaN |
| Less accumulated depreciation | 119 | 116 | 112 | NaN |
| Property and equipment, net | 416 | 418 | 420 | 424 |
| Operating lease right-of-use assets | 150 | 182 | 195 | 214 |
| Intangible asset, net (note 7) | 778 | 4,348 | 5,238 | 4,738 |
| Other noncurrent assets | 42 | 42 | 36 | 36 |
| Total assets | 7,442 | 20,274 | 13,807 | 14,382 |
| Accounts payable | 12,003 | 13,153 | 11,624 | 12,291 |
| Convertible notes (note 4)-Baker Bros Notes | 18,080 | 20,097 | 18,509 | 14,746 |
| Convertible notes (note 4)-Related Party | 843 | 1,352 | 983 | 35 |
| Convertible notes (note 4)-Adjuvant Notes | 33,384 | 32,770 | 32,167 | 31,933 |
| Short-term debt | NaN | 147 | 291 | 383 |
| Accrued expenses | 1,205 | 1,292 | 1,363 | 3,327 |
| Accrued compensation | 1,495 | 2,587 | 3,609 | 3,249 |
| Operating lease liabilities current | 123 | 128 | 124 | 124 |
| Derivative liabilities | 1,168 | 1,006 | 1,140 | 3 |
| Contingent liabilities - current (note 7) | 220 | 272 | 215 | 213 |
| Other current liabilities | 10,231 | 12,016 | 8,161 | 7,589 |
| Total current liabilities | 78,752 | 84,820 | 78,186 | 73,893 |
| Operating lease liabilities noncurrent | 27 | 54 | 72 | 89 |
| Contingent liabilities - noncurrent (note 7) | 1,375 | 4,837 | 5,718 | 5,230 |
| Total liabilities | 80,154 | 89,711 | 83,976 | 79,212 |
| Convertible and redeemable preferred stock | 4,918 | 4,899 | 4,897 | 4,786 |
| Common stock, 0.0001 par value 3,000,000,000 shares authorized 132,530,081 and 126,685,925 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively | 13 | 13 | 12 | 12 |
| Additional paid-in capital | 831,875 | 831,859 | 831,816 | 831,424 |
| Accumulated other comprehensive loss | -6,643 | -8,818 | -6,718 | -2,556 |
| Accumulated deficit | -902,875 | -897,390 | -900,176 | -898,496 |
| Total stockholders deficit | -77,630 | -74,336 | -75,066 | -69,616 |
| Total liabilities, convertible and redeemable preferred stock and stockholders deficit | 7,442 | 20,274 | 13,807 | 14,382 |
Evofem Biosciences, Inc. (EVFM)
Evofem Biosciences, Inc. (EVFM)